Results 21 to 30 of about 11,434 (195)
Rescuing the last-line polymyxins: Achievements and challenges [PDF]
, 2021 Antibiotic resistance is a major global health challenge and, worryingly, several key Gram negative pathogens can become resistant to most currently available antibiotics.
Tony Zhou, Q +4 more
core +1 more source
mBio, 2021 Colistin (polymyxin E) and polymyxin B have been used as last-resort agents for treating infections caused by multidrug-resistant Gram-negative bacteria.
Zhizeng Sun, Timothy Palzkill
doaj +1 more source
Dissemination of MCR-Type Genes Encoding Polymyxin Resistance in Russia and Across the Globe
Антибиотики и Химиотерапия, 2021 The MCR-type polymyxin resistance gene localized on a mobile genetic element was described was described in 2015 for the first time. Publications, following the first description, demonstrated the global distribution of MCR-type genes and the role of ...
V. A. Ageevets +3 more
doaj +1 more source
Antibiotics, 2022 Pseudomonas aeruginosa infections are challenging to treat due to multi-drug resistance (MDR) and the complexity of the patients affected by these serious infections.
Aisling R. Caffrey +7 more
doaj +1 more source
Polymyxins resistance : an overview of molecular mechanisms and genetic determinants [PDF]
, 2021 Emergence of antimicrobial resistant bacteria is a majorworldwide public health issue. During the past decades, the misuse/overuse of antibiotics accelerated the development and dissemination of antimicrobial resistance, especially in multidrug-resistant
Cupertino, Victória Martins Lima
core +1 more source
Shifting Gears: The Future of Polymyxin Antibiotics
Antibiotics, 2019 The manuscripts contained in this special edition of Antibiotics represent a current review of the polymyxins as well as highlights from the 3rd International Polymyxin Conference, which was held in Madrid, Spain, 25 to 26 April 2018.
Justin R. Lenhard +3 more
doaj +1 more source
Transcriptomic Responses to Polymyxin B and Analogues in Human Kidney Tubular Cells
Antibiotics, 2023 Polymyxins are last-line antibiotics for the treatment of Gram-negative ‘superbugs’. However, nephrotoxicity can occur in up to 60% of patients administered intravenous polymyxins. The mechanisms underpinning nephrotoxicity remain unclear.
Mengyao Li +6 more
doaj +1 more source
Polymyxins: “Last Resort” for MDR and/or XDR Gram-Negative Infections [PDF]
, 2021 Polymyxins were used for the management of gram-negative infections in clinical practice science1940s. Parenteral administration waned in the seventies owing to polymyxins nephrotoxicity and neurotoxicity. Because of the lack of treatment choices for MDR
Ahmed, Manal Mohamed Elsayed +1 more
core +1 more source
Frontiers in Microbiology, 2020 Pseudomonas aeruginosa is an opportunistic human pathogen and a leading cause of nosocomial infections. Due to its high intrinsic and adaptive resistance to antibiotics, infections caused by this organism are difficult to treat and new therapeutic ...
Alessandra Vitale +7 more
doaj +1 more source
Synthesis and Evaluation of Polymyxins Bearing Reductively Labile Disulfide-Linked Lipids [PDF]
, 2022 Polymyxins are a class of lipopeptide anti-infective agents with potent and specific activity against Gram-negative bacteria. While toxicity concerns associated with polymyxin B and E (colistin) have historically limited their clinical application, today
Cornelis J. Slingerland (14069540) +18 more
core +3 more sources